Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant anti-CD25 humanized monoclonal antibody for prevention of GVHD after allogeneic HSCT
ChiCTR2600130418Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daclizumab in graft-versus-host disease (GVHD), sponsored by The Second Hospital of Hebei Medical University. Primary endpoint: Cumulative incidence of grade II–IV acute graft-versus-host disease (aGVHD). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
daclizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2600130418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130418.